Stocks to Watch: Nvidia Partners with SK Hynix, Marvell and Flex Join S&P 500
Several companies are experiencing notable stock movements due to partnerships and index changes, which could influence investor sentiment and market dynamics.
Roche
Preis: 51.35Unternehmen und Geschäftsmodell
Roche is a global healthcare company specializing in pharmaceuticals and diagnostics. Its core products include prescription medications, particularly in oncology, immunology, and neuroscience, as well as diagnostic tools for various diseases. Major business segments are Pharmaceuticals and Diagnostics, with primary revenue sources stemming from drug sales and diagnostic testing services. The company is known for its strong research and development capabilities, contributing to its innovative product pipeline.
Anlageprofil
Roche's investment profile is characterized by a balanced approach, appealing to investors seeking both growth and dividends. The company offers a stable dividend yield, making it attractive for income-focused investors, while its strong revenue growth indicates potential for capital appreciation. This combination positions Roche as suitable for those looking for a reliable investment with moderate risk.
Fundamentale Kennzahlen (experimentell)
- EPS (TTM) — Gewinn pro Aktie der letzten 12 Monate, $
- 2.73 OK
- Umsatz QoQ — Umsatzwachstum im Quartalsvergleich
- 90.4% ↑
- 20d Volatilität
- 1.8% stabil
- Dividendenrendite
- 3.1% moderat letzter Ex-Tag: 2026-03-13
FMP / FinFeed-Daten aktualisiert:
2026-06-11
Empf.: Kaufen
Potenzial: 63
Risiko: 40
Aktualisiert: 2026-06-11 05:39
Wie die Empfehlung funktioniert
Warum KI so denkt:
Stable dividend, moderate growth, uncertain market conditions.
Im Portfolio verfolgen
Preischart
KI-Empfehlung
Analystenprognose
Kalenderereignis
Positives Signal
Negatives Signal
Neutral / Update
Halten / informativ
B My buy
S My sell
Änderungen der AI-Empfehlung
| Datum | Vorher | Nachher | Grund |
|---|---|---|---|
| 2026-06-05 02:47 | Verkaufen | Kaufen | Strong revenue growth, but mixed momentum signals. |
| 2026-06-03 02:51 | Halten | Verkaufen | Weak momentum and high risk limit upside potential. |
| 2026-06-01 02:49 | Kaufen | Halten | Solid fundamentals, but mixed momentum signals present uncertainty. |
Analystenprognosen
| Datum | Analyst | Action | Ziel | Preis damals |
|---|---|---|---|---|
| 2025-12-10 11:17 | HSBC | Ziel erhöht | 50 → 57 | 48.66 |
| 2025-10-02 09:07 | HSBC | Bewertung angehoben | — → 50 | 44.83 |
Генеральный директор Roche Томас Шинеккер выражает обеспокоенность по поводу укрепления швейцарского франка на фоне падения продаж
Компания Roche сообщила о снижении продаж в первом квартале, что связано с укреплением швейцарского франка и конкуренцией со стороны дженериков для некоторых старых препаратов.